Journal article
B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy
Oncotarget, Vol.8(39), pp.66728-66741
2017
DOI: 10.18632/oncotarget.19271
PMCID: PMC5630450
PMID: 29029550
Abstract
B lymphoblastic leukemia/lymphoma (B-ALL) is a clonal hematopoietic stem cell neoplasm derived from B-cell progenitors, which mostly occurs in children and adolescents and is regarded as one of top leading causes of death related to malignancies in this population. Despite the majority of patients with B-ALL have fairly good response to conventional chemotherapeutic interventions followed by hematopoietic stem cell transplant for the last decades, a subpopulation of patients show chemo-resistance and a high relapse rate. Adult B-ALL exhibits similar clinical course but worse prognosis in comparison to younger individuals. Ample evidences have shown that the clinical behavior, response rate and clinical outcome of B-ALL rely largely on its genetic and molecular profiles, such as the presence of
BCR-ABL1
fusion gene which is an independent negative prognostic predictor. New B-ALL subtypes have been recognized with recurrent genetic abnormalities, including B-ALL with intrachromosomal amplification of chromosome 21 (iAMP21), B-ALL with translocations involving tyrosine kinases or cytokine receptors (“BCR-ABL1-like ALL”). Genome-wide genetic profiling studies on B-ALL have extended our understanding of genomic landscape of B-ALL, and genetic mutations involved in various key pathways have been illustrated. These include
CRLF2
and
PAX5
alterations
, TP53, CREBBP
and
ERG
mutations, characteristic genetic aberrations in BCR-ABL1-like B-ALL and others. The review further provides new insights into clinical implication of the genetic aberrations in regard to targeted therapy development.
Details
- Title: Subtitle
- B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy
- Creators
- Xiaohui Zhang - Moffitt Cancer CenterPrerna Rastogi - University of IowaBijal Shah - Moffitt Cancer CenterLing Zhang - Moffitt Cancer Center
- Resource Type
- Journal article
- Publication Details
- Oncotarget, Vol.8(39), pp.66728-66741
- DOI
- 10.18632/oncotarget.19271
- PMID
- 29029550
- PMCID
- PMC5630450
- NLM abbreviation
- Oncotarget
- ISSN
- 1949-2553
- eISSN
- 1949-2553
- Publisher
- Impact Journals LLC
- Language
- English
- Date published
- 2017
- Academic Unit
- Pathology
- Record Identifier
- 9984186668902771
Metrics
22 Record Views